Prospective Randomized Trial Investigating the Influence of Pharmaceutical Care on the Intra-Individual Variability of Tacrolimus Concentrations Early after Kidney Transplant

Therapeutic Drug Monitoring

Volumn 38, Issue 4, 2016, Pages 447-455

  Bessa, Adrieli B ^a   Felipe, Claudia R ^a   Hannun, Pedro ^a   Sayuri, Priscila ^a   Felix, Maria Julia ^a   Ruppel, Priscila ^a   Ferreira, Alexandra N ^a   Cristelli, Marina P ^a   Viana, Laila ^a   Mansur, Juliana F ^a   Basso, Geovana ^a   Aguiar, Wilson Ferreira ^a   Tedesco Silva, Hélio ^a   Medina Pestana, José ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

pharmaceutical care; pharmacokinetic; tacrolimus

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN; METHYLPREDNISOLONE; MYCOPHENOLIC ACID; PREDNISONE; TACROLIMUS; THYMOCYTE ANTIBODY; IMMUNOSUPPRESSIVE AGENT;

ACUTE GRAFT REJECTION; ADULT; ARTICLE; ASSESSMENT OF HUMANS; BASEL ASSESSMENT OF ADHERENCE TO IMMUNOSUPPRESSIVE MEDICATION SCALE; CONTROLLED STUDY; DIARRHEA; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; GRAFT FAILURE; GRAFT RECIPIENT; HOSPITAL READMISSION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; MIDDLE AGED; MINIMUM PLASMA CONCENTRATION; NURSING STAFF; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PHARMACEUTICAL CARE; PHARMACIST; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SEPSIS; SINGLE DRUG DOSE; VEIN THROMBOSIS; BLOOD; DRUG ADMINISTRATION; GRAFT REJECTION; PHARMACY; PROCEDURES;

ADULT; DRUG ADMINISTRATION SCHEDULE; FEMALE; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; MEDICATION ADHERENCE; MIDDLE AGED; PHARMACEUTICAL SERVICES; PROSPECTIVE STUDIES; TACROLIMUS; TRANSPLANT RECIPIENTS;

EID: 84961613804     PISSN: 01634356     EISSN: 15363694     Source Type: Journal    
DOI: 10.1097/FTD.0000000000000299     Document Type: Article

References (39)

1. Miura M, Niioka T, Kagaya H, et al. Pharmacogenetic determinants for interindividual difference of tacrolimus pharmacokinetics 1 year after renal transplantation. J Clin Pharm Ther. 2011;36:208
2. Anglicheau D, Flamant M, Schlageter MH, et al. Pharmacokinetic interaction between corticosteroids and tacrolimus after renal transplantation. Nephrol Dial Transplant. 2003;18:2409
3. Schiff J, Cole E, Cantarovich M. Therapeutic monitoring of calcineurin inhibitors for the nephrologist. Clin J Am Soc Nephrol. 2007;2:374
4. Shuker N, van Gelder T, Hesselink DA. Intra-Patient Variability in Tacrolimus Exposure: Causes, Consequences for Clinical Management. Orlando, FL: Transplant Rev; 2015
5. Gelder T. Within-patient variability in immunosuppressive drug exposure as a predictor for poor outcome after transplantation. Kidney Int. 2014; 85:1267
6. Pollock-BarZiv SM, Finkelstein Y, Manlhiot C, et al. Variability in tacrolimus blood levels increases the risk of late rejection and graft loss after solid organ transplantation in older children. Pediatr Transplant. 2010;14:968
7. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005; 353:487
8. Alloway RR, Dupuis R, Gabardi S, et al. Evolution of the role of the transplant pharmacist on the multidisciplinary transplant team. Am J Transplant. 2011;11:1576
9. Martin JE, Zavala EY. The expanding role of the transplant pharmacist in the multidisciplinary practice of transplantation. Clin Transplant. 2004; 18:50
10. Allemann SS, van Mil JW, Botermann L, et al. Pharmaceutical care: the PCNE definition 2013. Int J Clin Pharm. 2014;36:544
11. Joost R, Dörje F, Schwitulla J, et al. Intensified pharmaceutical care is improving immunosuppressive medication adherence in kidney transplant recipients during the first post-transplant year: a quasiexperimental study. Nephrol Dial Transplant. 2014;29:1597
12. Chisholm MA, Mulloy LL, Jagadeesan M, et al. Impact of clinical pharmacy services on renal transplant patients' compliance with immunosuppressive medications. Clin Transplant. 2001;15:330
13. Salgado TM, Moles R, Benrimoj SI, et al. Pharmacists' interventions in the management of patients with chronic kidney disease: a systematic review. Nephrol Dial Transplant. 2012;27:276
14. Chisholm-Burns MA, Spivey CA, Garrett C, et al. Impact of clinical pharmacy services on renal transplant recipients' adherence and outcomes. Patient Prefer Adherence. 2008;2:287
15. Marsicano Ede O, Fernandes Nda NS, Colugnati F, et al. Transcultural adaptation and initial validation of Brazilian-Portuguese version of the Basel assessment of adherence to immunosuppressive medications scale (BAASIS) in kidney transplants. BMC Nephrol. 2013;14:108
16. Park SI, Felipe CR, Pinheiro-Machado PG, et al. Circadian and timedependent variability in tacrolimus pharmacokinetics. Fundam Clin Pharmacol. 2007;21:191
17. Shuker N, Gelder TV, Hesselink DA. Intra-patient variability in tacrolimus exposure: causes, consequences for clinical management. Transplantation. 2015;29:78
18. Sapir-Pichhadze R, Wang Y, Famure O, et al. Time-dependent variability in tacrolimus trough blood levels is a risk factor for late kidney transplant failure. Kidney Int. 2013;85:1404
19. Hsiau M, Fernandez HE, Gjertson D, et al. Monitoring nonadherence and acute rejection with variation in blood immunosuppressant levels in pediatric renal transplantation. Transplantation. 2011;92:918
20. Park SI, Felipe CR, Pinheiro-Machado PG, et al. Tacrolimus pharmacokinetic drug interactions: effect of prednisone, mycophenolic acid or sirolimus. Fundam Clin Pharmacol. 2009;23:137
21. Felipe CR, Silva HT, Machado PG, et al. The impact of ethnic miscegenation on tacrolimus clinical pharmacokinetics and therapeutic drug monitoring. Clin Transplant. 2002;16:262
22. Kuypers DR, Claes K, Evenepoel P, et al. Time-related clinical determinants of long-term tacrolimus pharmacokinetics in combination therapy with mycophenolic acid and corticosteroids: a prospective study in one hundred de novo renal transplant recipients. Clin Pharmacokinet. 2004; 43:741
23. Scholten EM, Cremers SC, Schoemaker RC, et al. AUC-guided dosing of tacrolimus prevents progressive systemic overexposure in renal transplant recipients. Kidney Int. 2005;67:2440
24. Antignac M, Barrou B, Farinotti R, et al. Population pharmacokinetics and bioavailability of tacrolimus in kidney transplant patients. Br J Clin Pharmacol. 2007;64:750
25. Krombach T, Fischer V, Meyer UA. Cyclosporine metabolism in human liver: identification of a cytochrome P-450III gene family as the major cyclosporine-metabolizing enzyme explains interactions of cyclosporine with other drugs. Clin Pharmacol Ther. 1998;43:630
26. Sattler M, Guengerich FP, Yun CH, et al. Cytochrome P-450 3A enzymes are responsible for biotransformation of FK506 and rapamycin in man and rat. Drug Metab Dispos. 1992;20:753
27. Lamba JK, Lin YS, Schuetz EG, et al. Genetic contribution to variable human CYP3A-mediated metabolism. Adv Drug Deliv Rev. 2002;54:1271
28. Santoro A, Felipe CR, Tedesco-Silva H, et al. Pharmacogenetics of calcineurin inhibitors in Brazilian renal transplant patients. Pharmacogenomics. 2011;12:1293
29. Prendergast MB, Gaston RS. Optimizing medication adherence: an ongoing opportunity to improve outcomes after kidney transplantation. Clin J Am Nephrol. 2010;5:1305
30. Moreso F, Torres IB, Costa-Requena G, et al. Nonadherence to immunosuppression: challenges and solutions. Transplant Res Risk Manag. 2015;7:27
31. Dew MA, DiMartini AF, Vito Dabbs A, et al. Rates and risk factors for nonadherence to the medical regimen after adult solid organ transplantation. Transplantation. 2007;83:858
32. Massey EK, Tielen M, Laging M, et al. Discrepancies between Beliefs and behavior: a prospective study into immunosuppressive medication adherence after kidney transplantation. Transplantation. 2015;99:375
33. Couzi L, Moulin B, Morin MP, et al. Factors predictive of medication nonadherence after renal transplantation: a French observational study. Transplantation. 2013;95:326
34. Tielen M, Exel JV, Laging M, et al. Attitudes to medication after kidney transplantation and their association with medication adherence and graft survival: a 2-Year follow-up study. J Transplant. 2014;2014:675301
35. Chisholm-Burns MA, Spivey CA, Graff Zivin J, et al. Improving outcomes of renal transplant recipients with behavioral adherence contracts: a randomized controlled trial. Am J Transplant. 2013;13:2364
36. Cristelli MP, Tedesco-Silva H, Medina-Pestana JO, et al. Safety profile comparing azathioprine and mycophenolate in kidney transplant recipients receiving tacrolimus and corticosteroids. Trans Infect Dis. 2013; 15:369
37. Machado PG, Felipe CR, Hanzawa NM, et al. An open-label randomized trial of the safety and efficacy of sirolimus vs. azathioprine in living related renal allograft recipients receiving cyclosporine and prednisone combination. Clin Transplant. 2004;18:28
38. Nevins TE, Robiner WN, Thomas W. Predictive patterns of early medication adherence in renal transplantation. Transplantation. 2014;98:878
39. Chisholm-Burns MA, Spivey CA. Pharmacoadherence: a new term for a significant problem. Am J Health Syst Pharm. 2008;65:661